Changing the Landscape

Tonix Pharmaceuticals is developing next-generation medicines to help important public health challenges.

Tonix’s lead program is a Breakthrough Therapy designated-drug for the treatment of posttraumatic stress disorder.

Learn more

Latest News

Tonix Pharmaceuticals Presented Details of Newly Expanded Product Development Pipeline at 9th Annual Biotech Showcase Conference

• January 10, 2017 • 1:00 PM EST

Development Programs Include Phase 3-Ready Breakthrough Therapy TNX-102 SL, Designed for…

Read more

Management Team

Our experienced team has a strong track record of success in drug approvals and value creation.

View Management

Clinical Pipeline

Tonix's lead product candidate,TNX-102 SL, is being developed for the treatment of PTSD.

View Pipeline

About Tonix Pharmaceuticals

Tonix is developing innovative pharmaceutical products to address important public health challenges, with two programs focusing on posttraumatic stress disorder (PTSD). PTSD is a serious condition characterized by chronic disability, inadequate treatment options, and overall high utilization of healthcare services creating significant economic burden. Other development programs include TNX-801, a potential smallpox-preventing vaccine.

Learn more about tonix